159 results
Page 2 of 8
8-K
EX-99.1
09q0pt8p5vsyyv7w
14 Nov 23
Larimar Therapeutics Reports Third Quarter 2023 Operating and Financial Results
12:00am
8-K
c87bjix77xub
3 Oct 23
Departure of Directors or Certain Officers
4:31pm
8-K
EX-99.1
ommljjs3a9odyt
14 Aug 23
Other Events
8:00am
8-K
EX-99.1
r8pb1
10 Aug 23
Larimar Therapeutics Reports Second Quarter 2023 Operating and Financial Results
7:03am
8-K
EX-99.1
97hjxd5zf5
25 Jul 23
Top-line safety, pharmacokinetic, and pharmacodynamic (frataxin level) data from Phase 2 trial’s 50 mg cohort expected in 1H 2024
7:02am
8-K
EX-99.2
fz321lzh04 je
25 Jul 23
Top-line safety, pharmacokinetic, and pharmacodynamic (frataxin level) data from Phase 2 trial’s 50 mg cohort expected in 1H 2024
7:02am
8-K
EX-99.1
i36wiheozs
17 Jul 23
Larimar Therapeutics Appoints Dr. Rusty Clayton as Chief Medical Officer
4:08pm
8-K
EX-99.1
0gggn6kp6edm0472ac
1 Jun 23
June 2023 Larimar Therapeutics Corporate Presentation
4:06pm
8-K
EX-99.1
99o w77bp8
15 May 23
Results of Operations and Financial Condition
7:05am
8-K
EX-99.2
3juym0taeslq
15 May 23
Results of Operations and Financial Condition
7:05am
8-K
EX-99.1
z393m9
10 Nov 22
Larimar Therapeutics Reports Third Quarter 2022 Operating and Financial Results
7:01am
8-K
EX-99.2
hetvfmis1yk0 khha
10 Nov 22
Larimar Therapeutics Reports Third Quarter 2022 Operating and Financial Results
7:01am
8-K
EX-99.1
0qs3qam2eox6v4q4rb
20 Oct 22
October 2022 Larimar Therapeutics Corporate Presentation
8:11am
424B5
nfca4t 1bph0n0860u
14 Sep 22
Prospectus supplement for primary offering
7:28am